Annovis Bio (ANVS) Competitors

$2.40 +0.12 (+5.04%)

Closing price 05/11/2026 03:59 PM Eastern

Extended Trading

$2.35 -0.05 (-2.09%)

As of 08:25 AM Eastern

ANVS vs. ALXO, KROS, FENC, MIST, and TENX

Should you be buying Annovis Bio stock or one of its competitors? The main competitors of Annovis Bio include ALX Oncology (ALXO), Keros Therapeutics (KROS), Adherex Technologies (FENC), Milestone Pharmaceuticals (MIST), and Tenax Therapeutics (TENX). These companies are all part of the "pharmaceutical products" industry.

How does Annovis Bio compare to ALX Oncology?

Annovis Bio (NYSE:ANVS) and ALX Oncology (NASDAQ:ALXO) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, profitability, dividends, earnings, valuation, institutional ownership and media sentiment.

Annovis Bio has a beta of 1.26, suggesting that its stock price is 26% more volatile than the broader market. Comparatively, ALX Oncology has a beta of 0.41, suggesting that its stock price is 59% less volatile than the broader market.

Annovis Bio is trading at a lower price-to-earnings ratio than ALX Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Annovis Bio	N/A	N/A	-$28.85M	-$1.40	N/A
ALX Oncology	N/A	N/A	-$101.69M	-$1.49	N/A

In the previous week, ALX Oncology had 11 more articles in the media than Annovis Bio. MarketBeat recorded 12 mentions for ALX Oncology and 1 mentions for Annovis Bio. ALX Oncology's average media sentiment score of 0.07 beat Annovis Bio's score of 0.00 indicating that ALX Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Annovis Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ALX Oncology	1 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Annovis Bio presently has a consensus price target of $13.50, indicating a potential upside of 463.67%. ALX Oncology has a consensus price target of $4.60, indicating a potential upside of 121.15%. Given Annovis Bio's higher probable upside, analysts clearly believe Annovis Bio is more favorable than ALX Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Annovis Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
ALX Oncology	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

15.8% of Annovis Bio shares are owned by institutional investors. Comparatively, 98.0% of ALX Oncology shares are owned by institutional investors. 20.8% of Annovis Bio shares are owned by company insiders. Comparatively, 21.0% of ALX Oncology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Annovis Bio's return on equity of -159.43% beat ALX Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Annovis Bio	N/A	-159.43%	-133.49%
ALX Oncology	N/A	-197.20%	-112.45%

Summary

ALX Oncology beats Annovis Bio on 8 of the 13 factors compared between the two stocks.

How does Annovis Bio compare to Keros Therapeutics?

Annovis Bio (NYSE:ANVS) and Keros Therapeutics (NASDAQ:KROS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, valuation, dividends, institutional ownership, earnings and media sentiment.

Annovis Bio has a beta of 1.26, suggesting that its share price is 26% more volatile than the broader market. Comparatively, Keros Therapeutics has a beta of 0.95, suggesting that its share price is 5% less volatile than the broader market.

15.8% of Annovis Bio shares are owned by institutional investors. Comparatively, 71.6% of Keros Therapeutics shares are owned by institutional investors. 20.8% of Annovis Bio shares are owned by company insiders. Comparatively, 22.9% of Keros Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Keros Therapeutics has higher revenue and earnings than Annovis Bio. Annovis Bio is trading at a lower price-to-earnings ratio than Keros Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Annovis Bio	N/A	N/A	-$28.85M	-$1.40	N/A
Keros Therapeutics	$244.06M	0.97	$87.01M	$1.82	6.60

In the previous week, Annovis Bio and Annovis Bio both had 1 articles in the media. Keros Therapeutics' average media sentiment score of 1.89 beat Annovis Bio's score of 0.00 indicating that Keros Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Annovis Bio	Neutral
Keros Therapeutics	Very Positive

Annovis Bio presently has a consensus price target of $13.50, indicating a potential upside of 463.67%. Keros Therapeutics has a consensus price target of $20.40, indicating a potential upside of 69.86%. Given Annovis Bio's higher possible upside, equities research analysts plainly believe Annovis Bio is more favorable than Keros Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Annovis Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Keros Therapeutics	1 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25

Keros Therapeutics has a net margin of 35.65% compared to Annovis Bio's net margin of 0.00%. Keros Therapeutics' return on equity of 14.25% beat Annovis Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Annovis Bio	N/A	-159.43%	-133.49%
Keros Therapeutics	35.65%	14.25%	13.27%

Summary

Keros Therapeutics beats Annovis Bio on 11 of the 13 factors compared between the two stocks.

How does Annovis Bio compare to Adherex Technologies?

Annovis Bio (NYSE:ANVS) and Adherex Technologies (NASDAQ:FENC) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, valuation, dividends, institutional ownership, earnings and media sentiment.

Annovis Bio has a beta of 1.26, suggesting that its share price is 26% more volatile than the broader market. Comparatively, Adherex Technologies has a beta of 0.91, suggesting that its share price is 9% less volatile than the broader market.

15.8% of Annovis Bio shares are owned by institutional investors. Comparatively, 55.5% of Adherex Technologies shares are owned by institutional investors. 20.8% of Annovis Bio shares are owned by company insiders. Comparatively, 10.7% of Adherex Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Adherex Technologies had 2 more articles in the media than Annovis Bio. MarketBeat recorded 3 mentions for Adherex Technologies and 1 mentions for Annovis Bio. Adherex Technologies' average media sentiment score of 0.63 beat Annovis Bio's score of 0.00 indicating that Adherex Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Annovis Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Adherex Technologies	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Annovis Bio has a net margin of 0.00% compared to Adherex Technologies' net margin of -22.62%. Annovis Bio's return on equity of -159.43% beat Adherex Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Annovis Bio	N/A	-159.43%	-133.49%
Adherex Technologies	-22.62%	-183.18%	-15.31%

Annovis Bio presently has a consensus price target of $13.50, indicating a potential upside of 463.67%. Adherex Technologies has a consensus price target of $14.80, indicating a potential upside of 108.45%. Given Annovis Bio's higher possible upside, equities research analysts plainly believe Annovis Bio is more favorable than Adherex Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Annovis Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Adherex Technologies	2 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.57

Adherex Technologies has higher revenue and earnings than Annovis Bio. Adherex Technologies is trading at a lower price-to-earnings ratio than Annovis Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Annovis Bio	N/A	N/A	-$28.85M	-$1.40	N/A
Adherex Technologies	$44.64M	5.49	-$9.74M	-$0.34	N/A

Summary

Adherex Technologies beats Annovis Bio on 10 of the 16 factors compared between the two stocks.

How does Annovis Bio compare to Milestone Pharmaceuticals?

Milestone Pharmaceuticals (NASDAQ:MIST) and Annovis Bio (NYSE:ANVS) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, dividends, earnings, institutional ownership and profitability.

Milestone Pharmaceuticals currently has a consensus price target of $7.50, suggesting a potential upside of 294.74%. Annovis Bio has a consensus price target of $13.50, suggesting a potential upside of 463.67%. Given Annovis Bio's higher possible upside, analysts plainly believe Annovis Bio is more favorable than Milestone Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Milestone Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Annovis Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Milestone Pharmaceuticals has a beta of 1.04, suggesting that its stock price is 4% more volatile than the broader market. Comparatively, Annovis Bio has a beta of 1.26, suggesting that its stock price is 26% more volatile than the broader market.

In the previous week, Milestone Pharmaceuticals had 4 more articles in the media than Annovis Bio. MarketBeat recorded 5 mentions for Milestone Pharmaceuticals and 1 mentions for Annovis Bio. Milestone Pharmaceuticals' average media sentiment score of 0.37 beat Annovis Bio's score of 0.00 indicating that Milestone Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Milestone Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Annovis Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

86.2% of Milestone Pharmaceuticals shares are held by institutional investors. Comparatively, 15.8% of Annovis Bio shares are held by institutional investors. 19.5% of Milestone Pharmaceuticals shares are held by insiders. Comparatively, 20.8% of Annovis Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Annovis Bio's return on equity of -159.43% beat Milestone Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Milestone Pharmaceuticals	N/A	-656.73%	-81.19%
Annovis Bio	N/A	-159.43%	-133.49%

Annovis Bio has lower revenue, but higher earnings than Milestone Pharmaceuticals. Milestone Pharmaceuticals is trading at a lower price-to-earnings ratio than Annovis Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Milestone Pharmaceuticals	$1.55M	146.66	-$63.06M	-$0.79	N/A
Annovis Bio	N/A	N/A	-$28.85M	-$1.40	N/A

Summary

Milestone Pharmaceuticals beats Annovis Bio on 9 of the 15 factors compared between the two stocks.

How does Annovis Bio compare to Tenax Therapeutics?

Annovis Bio (NYSE:ANVS) and Tenax Therapeutics (NASDAQ:TENX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, valuation, institutional ownership, profitability and risk.

15.8% of Annovis Bio shares are held by institutional investors. Comparatively, 1.7% of Tenax Therapeutics shares are held by institutional investors. 20.8% of Annovis Bio shares are held by insiders. Comparatively, 3.7% of Tenax Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Annovis Bio has a beta of 1.26, suggesting that its share price is 26% more volatile than the broader market. Comparatively, Tenax Therapeutics has a beta of 1, suggesting that its share price has a similar volatility profile to the broader market.

Tenax Therapeutics' return on equity of -51.83% beat Annovis Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Annovis Bio	N/A	-159.43%	-133.49%
Tenax Therapeutics	N/A	-51.83%	-49.51%

Tenax Therapeutics is trading at a lower price-to-earnings ratio than Annovis Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Annovis Bio	N/A	N/A	-$28.85M	-$1.40	N/A
Tenax Therapeutics	N/A	N/A	-$52.60M	-$1.33	N/A

Annovis Bio currently has a consensus price target of $13.50, suggesting a potential upside of 463.67%. Tenax Therapeutics has a consensus price target of $29.67, suggesting a potential upside of 148.26%. Given Annovis Bio's higher probable upside, equities research analysts plainly believe Annovis Bio is more favorable than Tenax Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Annovis Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Tenax Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

In the previous week, Tenax Therapeutics had 6 more articles in the media than Annovis Bio. MarketBeat recorded 7 mentions for Tenax Therapeutics and 1 mentions for Annovis Bio. Tenax Therapeutics' average media sentiment score of 0.18 beat Annovis Bio's score of 0.00 indicating that Tenax Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Annovis Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tenax Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Tenax Therapeutics beats Annovis Bio on 8 of the 14 factors compared between the two stocks.

Get Annovis Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ANVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ANVS vs. The Competition

Export

Metric	Annovis Bio	MED Industry	Medical Sector	NYSE Exchange
Market Cap	$79.00M	$3.39B	$6.24B	$22.90B
Dividend Yield	N/A	2.25%	2.78%	4.03%
P/E Ratio	-1.71	15.06	20.63	28.91
Price / Sales	N/A	306.19	541.17	108.04
Price / Cash	N/A	56.93	27.81	19.21
Price / Book	3.74	6.94	9.64	4.65
Net Income	-$28.85M	$24.11M	$3.54B	$1.07B
7 Day Performance	4.86%	-0.90%	-0.23%	-0.14%
1 Month Performance	51.10%	4.62%	6.28%	3.95%
1 Year Performance	55.62%	72.73%	39.17%	25.39%

Annovis Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ANVS Annovis Bio	2.0596 of 5 stars	$2.40 +5.0%	$13.50 +463.7%	+56.0%	$79.00M	N/A	N/A	3	Upcoming Earnings
ALXO ALX Oncology	3.0575 of 5 stars	$1.88 +11.2%	$4.60 +144.7%	+392.5%	$227.41M	N/A	N/A	40	Earnings Report Analyst Upgrade
KROS Keros Therapeutics	3.7708 of 5 stars	$11.71 +1.9%	$21.33 +82.2%	-12.0%	$227.36M	$244.06M	6.43	100
FENC Adherex Technologies	4.0618 of 5 stars	$6.65 +1.7%	$14.80 +122.6%	+18.9%	$225.90M	$44.64M	N/A	10	Upcoming Earnings
MIST Milestone Pharmaceuticals	2.741 of 5 stars	$1.90 +1.3%	$7.50 +295.8%	+71.2%	$220.04M	$1.55M	N/A	30	Positive News Upcoming Earnings Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:ANVS) was last updated on 5/12/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Annovis Bio (ANVS) Competitors

ANVS vs. ALXO, KROS, FENC, MIST, and TENX

How does Annovis Bio compare to ALX Oncology?

Summary

How does Annovis Bio compare to Keros Therapeutics?

Summary

How does Annovis Bio compare to Adherex Technologies?

Summary

How does Annovis Bio compare to Milestone Pharmaceuticals?

Summary

How does Annovis Bio compare to Tenax Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANVS vs. The Competition

Annovis Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Annovis Bio (ANVS) Competitors

ANVS vs. ALXO, KROS, FENC, MIST, and TENX

How does Annovis Bio compare to ALX Oncology?

Which has more risk and volatility, ANVS or ALXO?

Which has stronger earnings & valuation, ANVS or ALXO?

Does the media refer more to ANVS or ALXO?

Do analysts prefer ANVS or ALXO?

Do insiders and institutionals have more ownership in ANVS or ALXO?

Is ANVS or ALXO more profitable?

Summary

How does Annovis Bio compare to Keros Therapeutics?

Which has more volatility & risk, ANVS or KROS?

Do institutionals and insiders have more ownership in ANVS or KROS?

Which has higher earnings and valuation, ANVS or KROS?

Does the media refer more to ANVS or KROS?

Do analysts rate ANVS or KROS?

Is ANVS or KROS more profitable?

Summary

How does Annovis Bio compare to Adherex Technologies?

Which has more volatility & risk, ANVS or FENC?

Do institutionals and insiders have more ownership in ANVS or FENC?

Does the media refer more to ANVS or FENC?

Is ANVS or FENC more profitable?

Do analysts rate ANVS or FENC?

Which has higher earnings and valuation, ANVS or FENC?

Summary

How does Annovis Bio compare to Milestone Pharmaceuticals?

Do analysts recommend MIST or ANVS?

Which has more volatility & risk, MIST or ANVS?

Does the media favor MIST or ANVS?

Do insiders & institutionals hold more shares of MIST or ANVS?

Is MIST or ANVS more profitable?

Which has better valuation and earnings, MIST or ANVS?

Summary

How does Annovis Bio compare to Tenax Therapeutics?

Do institutionals & insiders hold more shares of ANVS or TENX?

Which has more risk & volatility, ANVS or TENX?

Is ANVS or TENX more profitable?

Which has preferable valuation & earnings, ANVS or TENX?

Do analysts prefer ANVS or TENX?

Does the media favor ANVS or TENX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANVS vs. The Competition

Annovis Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools